A Randomized, Double-Masked Study on the Treatment of Retinal Vein Occlusion With Troxerutin

Glacet–Bernard, A.; Coscas, G.; Chabanel, A.; Zourdani, Ali; Lelong, F.; Samama, M

doi:10.1016/s0002-9394(14)75791-5

Cited by 77 publications

(33 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All patients also had subsidiary treatment with pentoxifylline, salicylic acid and ascorbic acid. Although the evidence for this subsidiary treatment is very weak, some authors have reported a possible benefit of rheological and antithrombotic therapy [24] . Since all eyes received this treatment, it did not influence the statistical evaluation.…”

Section: Discussionmentioning

confidence: 99%

Initial Visual Acuity Is an Important Prognostic Factor in Patients with Branch Retinal Vein Occlusion

et al. 2010

View full text Add to dashboard Cite

Purpose: To evaluate the role of initial visual acuity (VA) as a potential prognostic factor for final VA in patients with branch retinal vein occlusion (BRVO). Methods: A retrospective data analysis involving 163 patients with macular edema secondary to BRVO treated according to the recommendations of the Branch Vein Occlusion Study Group was performed using univariate and multivariate logistic regression models, and receiver-operating characteristics analysis. The analyses take factors into account that can potentially influence final visual result: sex, age, type of occlusion (major temporal or macular), grid photocoagulation and ischemia. Results: The final VA ≤0.1 was statistically significantly related to initial VA ≤0.16 and age >70 years. Sex, type of occlusion, grid photocoagulation and ischemia did not significantly influence the prediction of final VA based on age and initial VA. Conclusions: The analysis shows that initial VA and age >70 years significantly influence the prognosis for final visual results in patients with BRVO.

show abstract

Section: Discussionmentioning

confidence: 99%

Initial Visual Acuity Is an Important Prognostic Factor in Patients with Branch Retinal Vein Occlusion

et al. 2010

View full text Add to dashboard Cite

show abstract

“…In patients with markedly elevated fibrinogen concentration, one should consider additional therapy with fibrinogen reducing agents [50]. In addition, rheological therapy was found to have a beneficial effect in retinal vascular occlusions [51][52][53].…”

Section: Discussionmentioning

confidence: 99%

Prothrombotic states associated with retinal venous occlusion in young adults

et al. 1997

View full text Add to dashboard Cite

Background. The etiology of retinal venous occlusion in young patients is not well understood although thrombosis does occur histologically. A search for the risk factors that may lead to thrombosis is highly desirable may contribute to our understanding of the pathogenesis of this complication and may improve our therapeutic strategies. Methods. We studied 17 patients with retinal venous occlusion. All patients were under 45 years of age (mean 37.8 4-7.1). Antiphospholipid antibodies (APAs) and certain hemostatic factors were determined. The results obtained in these patients were compared to those of normal controls. Results. We found APAs in 8 out of 17 patients compared to 5 out of 60 controls (p = 0.0002). In patients with major trunk occlusion, there was a trend for the presence of APAs in those with poor visual acuity at presentation. Deficiencies of the coagulation inhibitor proteins C and S and antithrombin III activities were detected in 6 patients, and reduced levels of Factor XII were found in 4 patients. Levels of hematocrit, erythrocyte sedimentation rate, Fibrinogen, cq-globulin, and ct2-globulin were significantly higher in patients compared to the controls (p --0.019; 0.014; 0.0001; 0.011; 0.047), indicating increased blood viscosity in patients with retinal venous occlusion. Conclusion: Prothrombotic changes in the form of APAs and/or deficiencies of coagulation inhibitors and Factor XII may contribute to the etiology of retinal venous occlusion in young adults. Young patients with retinal venous occlusion should be evaluated for these prothrombotic states.

show abstract

“…In clinical trials, troxerutin has been given in doses up to 7 g per day orally for up to 6 months with no contraindications (Glacet-Bernard et al 1994). It has been reported that during radiotherapy of head and neck cancer, administration of a mixture of troxerutin and coumarin offered protection to salivary glands and mucosa.…”

Section: Troxerutinmentioning

confidence: 99%

Role of Radioprotectors in the Inhibition of DNA Damage and Modulation of DNA Repair After Exposure to Gamma-Radiation

Devasagayam¹

2011

Selected Topics in DNA Repair

View full text Add to dashboard Cite

A Randomized, Double-Masked Study on the Treatment of Retinal Vein Occlusion With Troxerutin

Cited by 77 publications

References 17 publications

Initial Visual Acuity Is an Important Prognostic Factor in Patients with Branch Retinal Vein Occlusion

Initial Visual Acuity Is an Important Prognostic Factor in Patients with Branch Retinal Vein Occlusion

Prothrombotic states associated with retinal venous occlusion in young adults

Role of Radioprotectors in the Inhibition of DNA Damage and Modulation of DNA Repair After Exposure to Gamma-Radiation

Contact Info

Product

Resources

About